Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVELANT: Regorafenib After Failure of Lenvatinib in Unresectable Hepatocellular Carcinoma
KCT0011611Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Boryung. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0011611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011611.